Our Technology

Engineering Fit-for-Purpose Biotherapeutics

Our technology leverages Zymeworks’ industry leading expertise in the fields of protein engineering and drug chemistry to discover and develop the next generation of antibody-based therapeutics to combat unmet medical need in hard-to-treat cancers and other serious diseases.

The integration of complementary and antibody-based technologies, embedded in our proprietary Multispecific and Antibody-Drug Conjugate (ADC) therapeutic modalities, interfaced with disease biology, enables the development of differentiated and fit-for-purpose therapeutics.

Select Difficult-to-Treat Cancers & Target

Design with Complementary Technology

Optionality with Two Foundational Fit-for-Purpose Modalities

Zymeworks is an industry leader in both multispecific research and the use of this technology in developing therapeutics targeting areas of high unmet medical need.

Our clinically validated technologies harness the flexibility of our proprietary AZYMETRIC™ platform as a foundation to solve biological challenges.

Explore our technologies

The foundation to how we build and design multi-functional and unique antibodies
Customize and optimize the immune response to any antibody
Tumor‑specific immune co‑stimulation in a single, transferable, conditionally active design
Utilizing Azymetric™ to build differentiated and next generation T Cell Engagers